In this webinar recording, Dr Alexey Rak, Sanofi R&D, gives:
- an introduction to MMS technology and the principles of microseeding
- statistical examples of the crystallisation of small molecules-protein complexes and antibody-antigen complexes
- conclusions about the time- and cost-effectiveness of using microseeding in ambitious structural biology labs.
Modern drug discovery processes require cost- and time-effective operation from structural biology teams to provide non-ambiguous solutions and support for structure-based rational drug design projects. Protein crystallisation success rates and improvements in crystallisation optimisation time can positively influence drug discovery.
In Sanofi’s R&D labs, Dr Rak achieves this by applying microseeding crystallisation techniques assisted by the mosquito robot (TTP Labtech). Together, these have been demonstrated to improve the quality of protein crystals and are used instead of, or in concert with, routine crystallisation optimisation. Microseeding is applied to the generation of new ligand bound crystal forms as well as to crystallising proteins and protein complexes which were not otherwise possible to crystallise.